Prof. Roberto Iacovelli: Drug interruptions in mRCC IO-TKI (Avelumab and axitinib) is safe and may reduce toxicity and cost for the treatment

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with Prof. Roberto Iacovelli (IT), Gostino Gemelli University Polyclinic, Rome, about the abstract he presented at ESMO 2023, "The TIDE-A study: Phase II study of avelumab (Ave) plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma". Prof. Iacovelli shares details on the TIDE-A study, the first study demonstrating the potential benefits of VEGFR-TKI interruption combined...